Tu banner alternativo

LSP2-9166

The topic of LSP2-9166 is of great interest and relevance in today's world. It is a topic that covers multiple aspects and has a significant impact on society, the economy, politics and culture. Throughout history, LSP2-9166 has been the subject of debate, analysis and study, demonstrating its importance in different contexts. In this article, we will explore the different facets of LSP2-9166, examining its influence in various areas of life. Whether at an individual or collective level, LSP2-9166 awakens the interest of a wide audience, generating reflection and debate about its meaning and consequences today.

Tu banner alternativo
LSP2-9166
Identifiers
  • (2S)-2-amino-4--hydroxymethyl]-hydroxyphosphoryl]butanoic acid
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC14H17F3NO9P
Molar mass431.257 g·mol−1
3D model (JSmol)
  • C1=CC(=C(C=C1C(O)P(=O)(CC(C(=O)O)N)O)OC(F)(F)F)OCC(=O)O
  • InChI=1S/C14H17F3NO9P/c15-14(16,17)27-10-5-7(1-2-9(10)26-6-11(19)20)13(23)28(24,25)4-3-8(18)12(21)22/h1-2,5,8,13,23H,3-4,6,18H2,(H,19,20)(H,21,22)(H,24,25)/t8-,13?/m0/s1
  • Key:NTRJZUQSNSIKLO-OADYLZGLSA-N

LSP2-9166 is a drug which acts as a selective agonist for the group III metabotropic glutamate receptors, with a reasonably potent EC50 of 70nM at mGluR4 and 220nM at mGluR7, and weaker activity of 1380nM at mGluR6 and 4800nM at mGluR8.[1] It has anticonvulsant effects in animal studies,[2][3] and reduces self-administration of various addictive drugs.[4][5][6]


References

  1. ^ Acher FC, Cabayé A, Eshak F, Goupil-Lamy A, Pin JP (February 2022). "Metabotropic glutamate receptor orthosteric ligands and their binding sites". Neuropharmacology. 204 108886. doi:10.1016/j.neuropharm.2021.108886. PMID 34813860.
  2. ^ Girard B, Tuduri P, Moreno MP, Sakkaki S, Barboux C, Bouschet T, et al. (September 2019). "The mGlu7 receptor provides protective effects against epileptogenesis and epileptic seizures". Neurobiology of Disease. 129: 13–28. doi:10.1016/j.nbd.2019.04.016. PMID 31051234.
  3. ^ Kovalenko AA, Zakharova MV, Schwarz AP, Dyomina AV, Zubareva OE, Zaitsev AV (March 2022). "Changes in Metabotropic Glutamate Receptor Gene Expression in Rat Brain in a Lithium-Pilocarpine Model of Temporal Lobe Epilepsy". International Journal of Molecular Sciences. 23 (5): 2752. doi:10.3390/ijms23052752. PMC 8910969. PMID 35269897.
  4. ^ Hajasova Z, Canestrelli C, Acher F, Noble F, Marie N (March 2018). "Role of mGlu7 receptor in morphine rewarding effects is uncovered by a novel orthosteric agonist". Neuropharmacology. 131: 424–430. doi:10.1016/j.neuropharm.2018.01.002. PMID 29307544. S2CID 3391450.
  5. ^ Lebourgeois S, Vilpoux C, Jeanblanc J, Acher F, Marie N, Noble F, Naassila M (May 2018). "Pharmacological activation of mGlu4 and mGlu7 receptors, by LSP2-9166, reduces ethanol consumption and relapse in rat". Neuropharmacology. 133: 163–170. doi:10.1016/j.neuropharm.2018.01.031. PMID 29378211. S2CID 3959313.
  6. ^ De Sa Nogueira D, Bourdy R, Filliol D, Quessada C, McCort-Tranchepain I, Acher F, et al. (November 2021). "LSP2-9166, an orthosteric mGlu4 and mGlu7 receptor agonist, reduces cocaine self-administration under a progressive ratio schedule in rats" (PDF). Neuroscience Letters. 764 135603. doi:10.1016/j.neulet.2020.135603. PMID 33387661. S2CID 229724310.


Stub icon

This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia